Sign inJoin waitlistJoin the waitlist

Claudia Chiriboga

Professor of Neurology and Pediatrics (in the Gertrude H. Sergievsky Center) at CUMC · Columbia Univ Coll of Phys & Surgeons

Credentials: · · · ·

History

Columbia Univ Coll of Phys & Surgeons · New York Presbyterian Hospital
Present

SAINT LUKES ROOSEVELT HOSPITAL
1987–1991
Child Neurology
New York Presbyterian Hospital
1982–1987
Mailman School of Public Health, Columbia University
University of Buenos Aires Medical School
1978–1982

Research

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
New England Journal of Medicine · 2017 · 1,769 citations
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
New England Journal of Medicine · 2018 · 1,080 citations
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
The Lancet · 2016 · 775 citations

Darryl De Vivo
19 papers
BD
Basil Darras
14 papers
Jacqueline Montes
14 papers
Richard Finkel
14 papers
Susan Iannaccone
10 papers
KS
Kathryn Swoboda
7 papers
Perry Shieh
7 papers
Anne Connolly
6 papers
Nancy Kuntz
6 papers
SY
Sally Young
6 papers
AS
Ai Sakonju
5 papers
AP
Amy Pasternak
5 papers

Grants

Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT Sites) (U24 Clinical Trial Not Allowed)
National Institute of Neurological Disorders and Stroke · U24
PI · $3.4M · Columbia University Health Sciences
2018–2028
Columbia University Medical Center - Weill Cornell Medical Center NEXT Site
National Institute of Neurological Disorders and Stroke · U10
PI · $2.2M · Columbia University Health Sciences
2011–2018
Quantified Fetal Cocaine Exposure and Neurodevelopment
National Institute on Drug Abuse · R01
Contact PI · $3.3M · Columbia University Health Sciences
1999–2006
In utero Cocaine Exposures--Neurodevelopement
National Institute of Neurological Disorders and Stroke · K08
Contact PI · $443.1K · Columbia University Health Sciences
1991–1997

Clinical trials

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
Principal investigator · Completed · Phase 2, Phase 3
Columbia University
2012–2015
Miglustat in Niemann-Pick Type C Disease
Principal investigator · Completed · Phase 2
Actelion
2002–2008
ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
Site PI · Recruiting · Phase 4
Novartis Pharmaceuticals
2026–2032
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Site PI · Recruiting · Phase 2
argenx
2025–2029